Please login to the form below

Not currently logged in
Email:
Password:

lupus

This page shows the latest lupus news and features for those working in and with pharma, biotech and healthcare.

New data backs Merck’s segue into MS with BTK inhibitor

New data backs Merck’s segue into MS with BTK inhibitor

That mechanism also forms the basis of Merck’s testing of evobrutinib in rheumatoid arthritis and systemic lupus erythematosus (SLE), also at the phase 2 stage.

Latest news

More from news
Approximately 8 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus. ... 230. SuppreMol / Baxter. Company acquisition. Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid arthritis) stated: “Getting a correct diagnosis was

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    886. Ablynx  / AbbVie. 1. Licence. ALX0061 - anti-IL-6R nanobody for rheumatoid arthritis and lupus.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics